Drug Approval | July 14, 2023
Lupin receives approval from USFDA for Chlorpromazine Hydrochloride Tablets USP
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
Approval to dramatically change CAR-T therapies landscape
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Advances clinical research capabilities with leading regulatory grade registries platform
Cytel excels at using proven quantitative techniques to transform real-world data into actionable insights
This four-day course is designed for professionals in the pharmaceutical, nutraceutical, and related industries
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent
Subscribe To Our Newsletter & Stay Updated
